Naphthamidine urokinase plasminogen activator inhibitors with improved pharmacokinetic properties.
Bruncko, M., McClellan, W.J., Wendt, M.D., Sauer, D.R., Geyer, A., Dalton, C.R., Kaminski, M.A., Weitzberg, M., Gong, J., Dellaria, J.F., Mantei, R., Zhao, X., Nienaber, V.L., Stewart, K., Klinghofer, V., Bouska, J., Rockway, T.W., Giranda, V.L.(2005) Bioorg Med Chem Lett 15: 93-98
- PubMed: 15582418 
- DOI: https://doi.org/10.1016/j.bmcl.2004.10.026
- Primary Citation of Related Structures:  
1U6Q - PubMed Abstract: 
A series of non-amide-linked 6-substituted-2-naphthamidine urokinase plasminogen activator (uPA) inhibitors are described. These compounds possess excellent binding activities and selectivities with significantly improved pharmacokinetic profiles versus previously described amide-linked inhibitors.
Organizational Affiliation: 
Cancer Research, Global Pharmaceutical R&D, Abbott Laboratories, 100 Abbott Park Road, Abbott Park, IL 60064-6101, USA. milan.bruncko@abbott.com